Our findings that BIBX1382, gefitinib and LY294002 reduced EGFR-mediated FDG uptake might also have relevance on the therapeutic effects of newer drugs for breast cancer that target EGFR [37, 46] or the PI3K pathway [47]. Here, EGFR is linked to breast cancer.